A small molecule inhibitor targeting the interaction between the oncogenic fusion protein EWS-FLI1 and its transcriptional partner DHX9 was developed for Ewing sarcoma treatment [79,89]. This evidence concerns the gene DHX9 and Ewing sarcoma.